Spark and Pfizer’s haemophilia gene therapy gets European PRIME statusDecision based on promising data from ongoing phase 1/2 trial. Share XSpark and Pfizer’s haemophilia gene therapy gets European PRIME statushttps://pharmaphorum.com/news/spark-pfizers-haemophilia-b-gene-therapy-gets-priority-medicines-access/